Antiretroviral treatment uptake in patients with HIV-associated TB attending co-located TB and ART services

M D Nglazi, R Kaplan, J Caldwell, N Peton, S D Lawn, R Wood, L-G Bekker

The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town
M D Nglazi, MPH
R Kaplan, MD
R Wood, MB BCh, MSc, FCP
L-G Bekker, MB ChB, FCP, PhD
S D Lawn, MD

International Union against Tuberculosis and Lung Disease, Paris, France
M D Nglazi, MPH

Department of City Health, City of Cape Town
J Caldwell, RN, RM, BCur

Provincial Government of the Western Cape, Cape Town
N Peton, MPA

Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK
S D Lawn, MD

Corresponding author: M Nglazi (Mweete.Nglazi@hiv-research.org.za)

Background. Delivery of integrated care for patients with HIV-associated TB is challenging. We assessed the uptake and timing of antiretroviral treatment (ART) among eligible patients attending a primary care service with co-located ART and TB clinics.

Methods. In a retrospective cohort study, all HIV-associated TB patients (≥18 years old) who commenced TB treatment in 2010 were included. Data were analysed using basic descriptive statistics and log-binomial regression analysis.

Results. Of a total of 497 patients diagnosed with HIV-associated TB, 274 were eligible to start ART for the first time (median CD4 count, 159 cells/µl). ART was started during TB treatment by 220 (80.3%) patients. Among the 54 (19.7%) who did not start ART, 23 (42.6%) were either lost to follow-up (LTFU) or died before enrolling for ART; 12 (22.2%) were either LTFU or died after enrolling but before starting ART; 5 (9.3%) were transferred out; and 14 (25.9%) only started ART after completion of TB treatment. The median delay between starting TB treatment and starting ART was 51 days (IQR 29 - 77). Overall, only 58.6% of patients started ART within 8 weeks of TB treatment, and 12.7% of those with CD4 counts <50 cells/µl started ART within 2 weeks.

Conclusions. In a setting with co-located TB and ART clinics, delays to starting ART were substantial, and one-fifth of eligible patients did not start ART during TB treatment. Co-location of services alone is insufficient to permit timely initiation of ART; further measures need to be implemented to facilitate integrated treatment.

Methods

Setting

The study was conducted at Nyanga Community Health Centre (CHC), Klipfontein health sub-district, Cape Town. An estimated 420 000 people live in this predominantly low-income urban community, which had an antenatal HIV-1 prevalence rate of 24% in 2009. This nurse-run, doctor-supported service has provided TB and ART care for patients since 2008. Here, TB treatment and ART is delivered by separate health authorities but located in the same building. Most ART-eligible co-infected patients receiving TB treatment at the TB clinic were referred to the ART clinic at the same site, and a minority were transferred-out to separate ART clinics in different localities in Cape Town.

The clinic staff at the TB service followed the South African National TB guidelines for TB case detection, notification and treatment. TB was treated using standardised rifampicin-based regimens of 6 months' duration for new TB cases and 8 months for retreatment cases. During the study period, the South African ART guidelines were revised: before April 2010, staff at both TB and ART services followed the 2004 South African ART guidelines which recommended that patients with CD4 counts of 50 - 200 cells/µl should delay ART until after 2 months of starting TB treatment, while those with a CD4 count <50 cells/µl or with serious co-morbidities should commence ART as soon as possible after at least 2 weeks of TB treatment. After April 2010, the clinic staff were advised to adopt the 2010 South African ART guidelines, which recommended that TB patients with CD4 cell counts <100 cells/µl or WHO stage IV should commence ART within 2 weeks of eligibility, and those with CD4 cell counts ≤350 cells/µl should commence ART within 2 - 8 weeks of starting TB treatment.

Data sources

The following data sources were used: (i) Western Cape’s electronic eKapa TB and ART database which is currently being used at this clinic. TB data in this database have been prospectively maintained since October 2009, including demographic and clinical information on TB patients and on TB treatment visits and outcomes per TB episode. HIV data have been prospectively maintained since March 2007, including demographic data and clinical data on patients’ ART treatment visits and outcomes. Both HIV and TB episodes are linked to patients using a unique identifier; (ii) paper-based TB register and the Western Cape’s electronic TB register (ETR.net) which monitors TB treatment; (iii) National Health Laboratory Services (NHLS) database; and (iv) patient records.

Data collection

All HIV-associated TB patients ≥18 years old who were registered and commenced on TB treatment between January 2010 and December 2010 were included. The Western Cape electronic data collection system, eKapa was used to obtain information on demographic characteristics (age and gender), clinical characteristics (TB disease classification, CD4 count and patient category) and TB treatment-related variables (date of starting TB treatment and regimen received). Information was also obtained on the uptake of ART and the time of ART initiation during TB treatment. Where information was missing, it was sought from patient records, NHLS database, paper based and electronic TB registers. Ethical clearance for the collection of routine data was obtained from the Research Ethics Committees of the University of Cape Town and the International Union against Tuberculosis and Lung Disease.

Definitions

Pre ART losses refer to failure to reach the next step in the care cascade from starting TB treatment to starting ART as a result of death and loss to follow-up (LTFU). Transfer to another TB and ART service was not regarded as a loss — patients who transfer are assumed to be retained.

Death refers to all-cause mortality.

Lost to follow-up refers to: (i) HIV-associated TB patients registered at the TB service who defaulted TB treatment for ≥8 weeks and failed to enrol in the ART service; (ii) HIV-associated TB patients who enrolled in the ART service but failed to attend the ART service for ≥12 weeks before starting ART; and (iii) patients classified as LTFU who were not known to have died or transferred to another facility.

ART eligibility was defined according to the South African national ART guidelines.

Statistical analyses

Statistical analyses were performed using STATA statistical software, version 11.0 (STATA Corporation, College Station, Texas, USA). Basic descriptive statistics were used to characterise uptake of ART (using proportions) and timing of ART during TB treatment (using median and interquartile ranges). Proportions of patients who started ART within specific time points were calculated and stratified by CD4 count. The CD4 count strata were categorized as <50 cells/µl, 50 - 200 cells/µl and 200 - 350 cells/µl according to the recent recommendations and guidelines. The time intervals considered were ART commencement between 2 and 8 weeks, and we determined the risk factors associated with starting ART after more than 8 weeks of TB treatment using log-binomial regression analysis.

Results

Patient characteristics

A total of 784 patients ≥18 years started TB treatment from January - December 2010 (Fig. 1). Of these, 10 had unknown HIV status, 277 were HIV-negative and 497 were HIV-positive. Among the 497 patients diagnosed with HIV-associated TB, 130 were already receiving ART at the time of diagnosis (Fig. 1). Of the 367 not yet on ART at the time of TB diagnosis, 363 had CD4 cell count information available. Because the South African ART guidelines were revised during the study period, ART eligibility was assessed using CD4 cell counts <200 cells/µl prior to April 2010, and CD4 cells counts ≤350 cells/µl after April 2010. Overall, 274 were ART eligible and therefore formed the patient cohort of this study that was followed up to determine if ART was initiated appropriately during TB treatment.

The patient cohort (N=274) characteristics at the time of start of TB treatment were: 51.8% of HIV-associated TB patients were female and of median age 34 years (interquartile range (IQR) 29 - 38) (Table 1). Immunodeficiency was advanced with a median blood CD4 lymphocyte count of 158.5 cells/µl (IQR 69 - 303); 73.4% co-infected patients had a new diagnosis of TB, and the majority of 194 (70.8%) were diagnosed as pulmonary TB of whom 50.0% were confirmed smear-negative TB (99/194).

Uptake of antiretroviral treatment

Of the 274 HIV-associated TB patients who were eligible to start ART for the first time (median CD4 count, 158.5 cells/µl), ART was started during TB treatment by 220 (80.3%) patients; 54 (19.7%) did not start ART (Fig. 1). Among the patients who did not start ART, 23 (42.6%) were LTFU or died prior to enrolment for ART; 12 (22.2%) were LTFU or died after enrolment but prior to starting ART; 5 (9.3%) were transferred-out; and 14 (25.9%) only started ART after completion of TB treatment.
Deaths
Among the 54 patients who did not start ART, 15 (27.8%) patients died; 13 died before enrolment for ART and 2 died after enrolment but prior to starting ART; 6 (40%) of the 15 patients who died had CD4 cell counts <50 cells/µl.

Time delays in starting antiretroviral treatment
Among the 220 known to have started ART during TB treatment, 215 had ART initiation dates recorded in patient records. Of these, the overall median time delay between starting TB treatment and starting ART was was 51 days (IQR 29 - 77). Because of the survival benefit of starting within 2 weeks of TB treatment in patients with CD4 counts <50 cells/µl and the national ART guideline recommendation to start ART within 8 weeks for those with CD4 counts <350 cells/µl, we examined delays in starting ART stratified by CD4 cell count. Among those with CD4 counts <50 cells/µl, we found that only 12.7% (7/55) of them had started ART within 2 weeks (Table 2). In those with CD4 counts of 50 - 200 cells/µl, 53.1% (85/160) started ART within 8 weeks.

Risk factors associated with starting ART after 8 weeks of TB treatment
We used univariate and multivariate analyses to determine the factors associated with starting ART after 8 weeks of TB treatment. Univariate analyses showed that patients with recurrent TB were 2.4 times (95% confidence interval (CI) 1.28 - 4.49) more likely to start ART after 8 weeks of TB treatment than those with new TB. The risk for starting ART after 8 weeks of TB treatment was higher among patients with CD4 cell counts of 50 - 200 cells/µl (risk ratio (RR) 2.29; 95% CI 1.12 - 4.66) and those with CD4 cell counts of 200 - 350 cells/µl (RR 3.49; 95% CI 1.51 - 8.07) compared with those with CD4 cell counts <50 cells/µl. Multivariate analyses showed similar results.

Discussion
In this study, we assessed the proportion of HIV-associated TB patients who successfully started ART and the timing of ART initiation during TB treatment. Of eligible patients, 19.7% (54/274) did not start ART. However, there were losses in the cascade from ART eligibility to ART initiation. Of eligible patients who did not start ART, 42.6% (23/54) were LTFU or died before enrolment for ART, and 22.2% (12/54) were LTFU or died after enrolment but prior to starting ART. The delay in starting ART was substantial (51 days) and exceeded the recommendations of the 2010 WHO and national ART guidelines,

examine delays in starting ART stratified by CD4 cell count. Among those with CD4 counts <50 cells/µl, we found that only 12.7% (7/55) of them had started ART within 2 weeks (Table 2). In those with CD4 counts of 50 - 200 cells/µl, 53.1% (85/160) started ART within 8 weeks.

Risk factors associated with starting ART after 8 weeks of TB treatment
We used univariate and multivariate analyses to determine the factors associated with starting ART after 8 weeks of TB treatment. Univariate analyses showed that patients with recurrent TB were 2.4 times (95% confidence interval (CI) 1.28 - 4.49) more likely to start ART after 8 weeks of TB treatment than those with new TB. The risk for starting ART after 8 weeks of TB treatment was higher among patients with CD4 cell counts of 50 - 200 cells/µl (risk ratio (RR) 2.29; 95% CI 1.12 - 4.66) and those with CD4 cell counts of 200 - 350 cells/µl (RR 3.49; 95% CI 1.51 - 8.07) compared with those with CD4 cell counts <50 cells/µl. Multivariate analyses showed similar results.

Discussion
In this study, we assessed the proportion of HIV-associated TB patients who successfully started ART and the timing of ART initiation during TB treatment. Of eligible patients, 19.7% (54/274) did not start ART. However, there were losses in the cascade from ART eligibility to ART initiation. Of eligible patients who did not start ART, 42.6% (23/54) were LTFU or died before enrolment for ART, and 22.2% (12/54) were LTFU or died after enrolment but prior to starting ART. The delay in starting ART was substantial (51 days) and exceeded the recommendations of the 2010 WHO and national ART guidelines,

Table 1. Baseline characteristics for TB/HIV co-infected ART-eligible patients ≥18 years old who started TB treatment in 2010

<table>
<thead>
<tr>
<th>Variables</th>
<th>N=274</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td></td>
</tr>
<tr>
<td>18 - 35</td>
<td>171 (62.4)</td>
</tr>
<tr>
<td>≥36</td>
<td>103 (37.6)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>142 (51.8)</td>
</tr>
<tr>
<td>Male</td>
<td>132 (48.1)</td>
</tr>
<tr>
<td>Patient category</td>
<td></td>
</tr>
<tr>
<td>New</td>
<td>201 (73.4)</td>
</tr>
<tr>
<td>Retreatment</td>
<td>73 (26.6)</td>
</tr>
<tr>
<td>Type of TB*</td>
<td></td>
</tr>
<tr>
<td>Smear-negative PTB</td>
<td>99 (36.1)</td>
</tr>
<tr>
<td>Smear-positive PTB</td>
<td>95 (34.7)</td>
</tr>
<tr>
<td>EPTB</td>
<td>80 (29.2)</td>
</tr>
<tr>
<td>CD4 count, cells/µl</td>
<td></td>
</tr>
<tr>
<td>&lt;50</td>
<td>68 (24.8)</td>
</tr>
<tr>
<td>50 - 200</td>
<td>140 (51.1)</td>
</tr>
<tr>
<td>&gt;200</td>
<td>66 (24.1)</td>
</tr>
<tr>
<td>TB regimen</td>
<td></td>
</tr>
<tr>
<td>Regimen 1</td>
<td>200 (73.0)</td>
</tr>
<tr>
<td>Regimen 2</td>
<td>74 (27.0)</td>
</tr>
</tbody>
</table>

PTB = pulmonary TB; EPTB = extra-pulmonary TB.

*Patients with no smears and having pulmonary TB were categorised as smear-negative pulmonary TB. Patients having both pulmonary and extra-pulmonary TB were categorised as having extra-pulmonary TB.

Fig. 1. Flow diagram showing uptake of ART treatment among HIV-associated TB patients. ART eligibility according to South African ART guidelines,22,23

Table 2. Duration of delays between starting TB treatment and starting ART among patients who initiated treatment with ART start date recorded and stratified by CD4 cell count category

<table>
<thead>
<tr>
<th>Duration of delay between starting TB treatment and starting ART</th>
<th>Patients with CD4 &lt;50 cells/µl (n=55)</th>
<th>Patients with CD4 50 - 200 cells/µl (n=114)</th>
<th>Patients with CD4 &gt;200 cells/µl (n=46)</th>
<th>All patients (N=215)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;2 weeks</td>
<td>7 (12.7)</td>
<td>6 (5.3)</td>
<td>2 (4.4)</td>
<td>15 (6.9)</td>
</tr>
<tr>
<td>&lt;4 weeks</td>
<td>20 (36.4)</td>
<td>25 (21.9)</td>
<td>8 (17.4)</td>
<td>53 (24.7)</td>
</tr>
<tr>
<td>&lt;6 weeks</td>
<td>30 (54.6)</td>
<td>46 (40.4)</td>
<td>11 (23.9)</td>
<td>87 (40.5)</td>
</tr>
<tr>
<td>&lt;8 weeks</td>
<td>41 (74.6)</td>
<td>64 (56.1)</td>
<td>21 (45.7)</td>
<td>126 (58.6)</td>
</tr>
<tr>
<td>&gt;8 weeks</td>
<td>14 (25.5)</td>
<td>50 (43.9)</td>
<td>25 (54.4)</td>
<td>89 (41.4)</td>
</tr>
</tbody>
</table>

PTB = pulmonary TB; EPTB = extra-pulmonary TB.
with CD4 cell counts <50 cells/µl. Therefore, despite co-locating TB and ART services, there are substantial delays in starting ART during TB treatment, and some patients did not start ART at all.

Our finding that 20% of eligible patients did not start ART lies within the range reported elsewhere in sub-Saharan Africa providing either separate or fully integrated services, of proportions of 13 - 86%,12,13,14,16,17 which shows that there are barriers to successful uptake of ART regardless of the model of care applied, and further measures must be implemented to facilitate efficient treatment integration. Of those not starting ART, 42.6% had died or were LTFU before enrolment for ART, and 20% of them died or were LTFU after enrolment but prior to starting ART. These data clearly indicate that retention in the stage in the cascade from ART eligibility to ART initiation must be improved. Retention might be improved by allowing ART services to dispense TB treatment and vice versa to streamline appointments and reduce duplication of services. Owing to the retrospective design of the study, the reasons for the reported losses are unknown. Possible reasons may include stigma, fear, lack of time to attend the clinic especially among those who work, and lack of transport money for additional clinic appointments.12,16. These factors might also have been induced by the presence of two health authorities rendering either TB or ART services that were not harmonised owing to organisational differences. Successful integration of TB and ART services may require integration at all levels in the health system from clinical care to community support and administrative structures.

We found an overall median delay in starting ART of 51 days, which is within the range of sub-Saharan Africa programmes providing either separate or fully integrated TB and ART services, of median delays between 44 and 110 days.12,13,14,16 While this median falls within the recommended 56 day cut-off, these patients have advanced HIV and more must be done within health systems to ensure earlier ART commencement. In particular, patients most at risk of AIDS mortality (CD4 counts <50 cells/µl) should be fast-tracked for ART; this may only be achieved if ART is prescribed and administered by the TB services.

The association between greater delays and higher CD4 cell counts is similar to a study16 among patients accessing separate TB and ART services in Cape Town, and is in keeping with the clinical recommendation that severely immunocompromised patients should be prioritised to initiate ART as soon as possible after starting TB treatment.

The study design include the tracking of losses at each stage in the cascade from start of TB treatment to start of ART, and time delays between starting TB treatment and starting ART in distinct services in this single primary health clinic. It provides an understanding of the strengths and limitations of an alternative model of TB and ART services and the importance of geographically co-locating these services, although not necessarily combining the services.

The study limitations are that there is no direct comparison with alternative models of either geographically separate or fully combined services: only one clinic with a relatively small sample size is considered, and the study does not quantify component delays associated with each step of the cascade from start of TB treatment to ART initiation. The retrospective design of the study does not enable us to determine the reasons for pre-ART losses among co-infected patients. Lastly, the uptake of ART among ineligible patients is unknown. Future studies will have to determine what happened to ART-ineligible patients.

Conclusions

ART services were included on the same premises that provided TB services at this primary health clinic in the hope of reducing delays in starting ART and improving ART uptake. However, this study found delays to starting ART were substantial, and a fifth of eligible patients did not start ART at all. These data show that the location of services alone is insufficient to permit timely initiation of ART, and further measures must be implemented to facilitate integrated treatment.

Acknowledgements. The authors gratefully acknowledge the dedicated staff of the Nyanga Community Health Centre. MDN is supported as an operational research fellow by the International Union Against Tuberculosis and Lung Disease, Paris, France. SD is funded by the Wellcome Trust, London UK. RW is funded in part by the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) funded by the National Institutes of Health (NIH, 5 R01AI058736-02), the International Epidemiologic Database to Evaluate AIDS with a grant from the National Institute of Allergy and Infectious Diseases (NIAID: SU01AI069924-02), USAID Right to Care (CA 674 A 00 08 0000 700) and the South African Centre for Epidemiological Modelling and Analysis (SACEMA).